Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP).

Javitt DC, Jayachandra M, Lindsley RW, Specht CM, Schroeder CE.

Clin Neurophysiol. 2000 May;111(5):833-6.

PMID:
10802454
2.
3.
4.

Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.

Mouri A, Noda Y, Enomoto T, Nabeshima T.

Neurochem Int. 2007 Jul-Sep;51(2-4):173-84. Epub 2007 Jun 27. Review.

PMID:
17669558
5.

Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia.

Javitt DC.

Audiol Neurootol. 2000 May-Aug;5(3-4):207-15. Review.

PMID:
10859415
6.

Contribution of AMPA and NMDA receptors to excitatory responses in the inferior colliculus.

Kelly JB, Zhang H.

Hear Res. 2002 Jun;168(1-2):35-42. Review.

PMID:
12117507
7.

The phencyclidine-glutamate model of schizophrenia.

Halberstadt AL.

Clin Neuropharmacol. 1995 Jun;18(3):237-49. Review.

PMID:
8635182
8.

PCP: from pharmacology to modelling schizophrenia.

Morris BJ, Cochran SM, Pratt JA.

Curr Opin Pharmacol. 2005 Feb;5(1):101-6. Review.

PMID:
15661633
9.

Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research.

Murray JB.

J Psychol. 2002 May;136(3):319-27. Review.

PMID:
12206280
10.

Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Javitt DC.

Ann N Y Acad Sci. 2015 May;1344:92-104. doi: 10.1111/nyas.12689. Epub 2015 Feb 26. Review.

Supplemental Content

Support Center